First Health Pharmaceuticals B.V. is a biotech company with its main offices in Amsterdam, the Netherlands. Considering the groundbreaking nature of the RNA Helicase targeting technology, developed by our group, and the vast array of pathogens and malignancies that is targeted by our compounds, it will come as no surprise that many research groups worldwide, directly or indirectly, participated in the research in our field of interest. Some of these collaborations are based on a joint development agreement but most academic groups performed efficacy tests related to pathogens that fit their field of research purely for academic reasons. Our research group is the only one in the world that developed a large portfolio of small molecule DDX3 Helicase inhibitors, for use both as antivirals and anti tumor agents. As such, many highly specialised research groups around the world are interested in testing our compounds, in order to gain more insight in the complex cellular RNA helicase biochemistry.
FIRST HEALTH GROUP
- First Health Pharmaceuticals B.V. – fully owned by the First Health Capital investment foundation
- First Health Capital – Investment Organisation and Holding of the First Health Group,
- First Health Participations – gives access to First Health stocks to private investors.
- First Health United – Independent Nonprofit Organisation (NPO) – receives donations and royalty-free access to First Health IP for Developing World.